GRI Bio

Q2 FY2026 EarningsQ2 FY26 bottom-line results exceeded consensus expectations, with a GAAP Net Loss of $1.64M vs. $2.15M expected, and a GAAP EPS of -$0.91 vs. -$1.20 consensus. The beat was primarily driven by lower-than-anticipated R&D expenditures ($0.41M) following the completion of the Phase 2a clinical trial for GRI-0621. While revenue remained at $0 in line with its clinical-stage status, the company maintained a cash balance of $10.95M, extending its runway through Q2 2027, though management continues to flag 'going concern' risks due to future funding requirements for pivotal trials.